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Abstract
Right ventricular failure (RVF) is an underestimated problem in
intensive care. This review explores the physiology and patho-
physiology of right ventricular function and the pulmonary
circulation. When RVF is secondary to an acute increase in
afterload, the picture is one of acute cor pulmonale, as occurs in
the context of acute respiratory distress syndrome, pulmonary
embolism and sepsis. RVF can also be caused by right myocardial
dysfunction. Pulmonary arterial catheterization and echocardio-
graphy are discussed in terms of their roles in diagnosis and
treatment. Treatments include options to reduce right ventricular
afterload, specific pulmonary vasodilators and inotropes.
Introduction
The lungs are the only organs to receive the entire cardiac
output. The role of the ‘right side of the heart’ is to accept the
blood from systemic circulation and pump it through the
pulmonary circulation. Even if the cardiac output from the right
and left sides of the heart are approximately equal (there is a
physiological shunt for the bronchial vessels), the way in which
these two cardiac outputs are conducted by the ventricles is
very different. Differences between the right and left sides of
the heart are multiple and numerous. These differences
contribute to both normal and abnormal physiology and
pathophysiology. Much attention has recently been directed
toward the left ventricle (LV), whereas the role played by the
right ventricle (RV) has remained comparatively neglected.
This is paradoxical when we consider that intensive care units
(ICUs) have been using a ‘right heart catheter’, namely the
pulmonary artery catheter (PAC), for more than 20 years. The
fundamental duty of an intensivist could be simplified to
ensuring that there is adequate cardiac output to systemic
circulation. This is clearly a goal that should be achieved in any
patient, but we should not discount the role of the pulmonary
circulation in cardiac homeostasis because the left and right
sides of the heart are interrelated in terms of function.
Important differences between right and left
sides of the heart
Anatomy
The right atrium (RA) and the RV form the right side of the
heart. The RA receives venous blood from superior and inferior
venae cavae, ejecting it through the pulmonary arteries. The
tricuspid and pulmonary valves prevent regurgitation into the
RA and RV, respectively. The right ventricular myocardium is
about one-third the thickness of its left counterpart because it
is a comparatively low pressure system. During systole, the LV
protrudes into the RV. These chambers are separated by the
septum and are surrounded by pericardium. These basic
anatomical arrangements explain why compliance of one
ventricle can modify that of the other. This interaction is known
as diastolic ventricular interaction and is important in
understanding the pathophysiology of right heart failure.
Physiology
In the average person, the systolic pressure of the RV reaches
a mere 25 mmHg, which is in contrast to the 120 mmHg
systolic pressure of the LV. This difference in pressure is
essentially due to the discrepancy in compliance between
pulmonary and systemic blood vessels, with pulmonary vessels
having a relatively large diameter and thin walls (conditions that
allow for the high compliance of the pulmonary system). Like
any vessel in the body, the pressure in the pulmonary system
depends on cardiac ouput, resistance and compliance. An
increase in pulmonary arterial pressure could be due to any
combination of increases in the first two factors or a decrease
in the third. The pulmonary vascular resistance has a particular
dependency on alveolar oxygen tension, whereby alveolar
hypoxia leads to pulmonary arterial vasoconstriction.
Pulmonary compliance has a value of about 2 ml/mmHg. This
allows the right heart to pump the blood with a blood
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pressure lower than the systemic arterial pressure, ensuring
that the pulmonary circulation is a ‘low pressure system’ [1].
Being a pump that works under low pressure conditions, the
RV is affected by an increase in afterload [2,3], even when
the oxygen consumption in the right heart is accounted for.
The RV is mainly perfused by the right coronary artery (RCA)
and partially by the left coronary arteries. The RCA is
perfused in both systolic and diastolic phases in the healthy
human as a result of the low systolic pressure (25 mmHg),
which does not occlude the vessel that has a systemic
pressure. When afterload is high, and therefore the pressure
necessary to contract the RV successfully is also high, partial
occlusion of the RCA may occur, leading to ischaemia.
Pathophysiology of right ventricular failure
Increased afterload
In ICUs there are many conditions that can lead to an increase
in right ventricular afterload. These include pulmonary embolism
(PE), positive pressure ventilation, acute respiratory distress
syndrome (ARDS) and increased pulmonary vascular resistance
(especially after cardiac surgery or in hypoventilatory states).
When there is an increase in right ventricular afterload, right
ventricular systole takes longer, even if the ejection time is
reduced. This elongated systole can last longer than left
ventricular systole. Because the RV is still contracting as the
left begins to relax, the septum displaces to the left while the
LV starts diastole and is moved back rightward when left
systole begins again. In summary, the net result is an
abnormal reversal of the left-to-right pressure gradient at end-
systole/onset of diastole and an altered cardiac performance
(Figure 1) [4]. Septal dyskinesia seen at echocardiography is
considered a sign of increased right ventricular afterload. This
mechanism involves the diastolic ventricular interaction.
Dilatation of right heart is a compensatory mechanism that
allows the RV to maintain stroke volume despite a decreased
ejection fraction [5,6]. When this enlargement is acute and
due to a sudden increase in afterload, it is termed acute cor
pulmonale. The two main causes are massive PE and ARDS
[7-9]. More importantly, when the underlying cause of acute
cor pulmonale is treated, the situation reverses [5]. If inter-
vention does not occur, enlargement of the RV can lead to
tricuspid annular dilatation with regurgitation, an increase in
right ventricular end-diastolic volume and leftward movement
of the septum, with final impairment of the LV [10]. This
progression can be rapid because the RV has a peculiar
auto-aggravation cycle. Tricuspid insufficiency can aggravate
splanchnic congestion, resulting in decreased venous return
and therefore preload. The cardiac output, already compro-
mised because of the low preload state of the LV induced by
the right ventricular failure (RVF), decreases further. Conse-
quential systemic hypotension exacerbates the impairment in
organ perfusion and coronary artery perfusion. Cardiac
ischaemia (commonly the next pathophysiological observa-
tion) is characterized by further aggravation of cardiac
performance and its cycle.
Pulmonary embolism
Acute PE represents an example of the aetiology of increased
right ventricular afterload. In massive embolism blood flow is
obstructed, resulting in a low cardiac output with systemic
hypotension. Jardin and coworkers [11] reported a study
conducted in 14 patients with massive PE. In these patients,
during the acute phase both the RA and the RV showed signs
of hypertrophy and elevated right atrial pressure, with reversal
of trans-septal diastolic pressure gradient. More importantly,
the LV was impeded by the leftward movement of the septum
and had a reduction in left ventricular diastolic area. As
described by Morris-Thurgood and Frenneaux [12], further
volume loading in this case can have detrimental effects
enhancing diastolic ventricular interaction. Belenkie and
colleagues [13] studied volume loading in a canine model,
before and after pulmonary embolization. After embolization,
volume loading moved the septum leftward and led to reduced
left ventricular area index and left ventricular stroke work.
Different findings were reported by Mercat and coworkers
[14]; they evaluated 30 patients with acute massive PE and
found that fluid loading (500 ml dextran 40) improved cardiac
output. The latter study highlighted the patients who improved
the most after the fluid loading, namely those who had a lower
right atrial pressure at baseline, which suggests that when an
interventricular dependency phenomenon was present there
was a lesser response to fluid loading. It is possibly untrue that
fluid loading should be avoided in the case of right ventricular
failure, but the fluid management should only correct hypo-
volaemia. Clinicians must be aware of the consequences of
excessive fluid loading, namely impairment in left ventricular (LV)
performance and worsening of the ‘auto-aggravation cycle’.
Mechanical ventilation
Intermittent positive pressure ventilation is often used
alongside treatments to optimize left ventricular function, with
benefits in terms of reductions in both preload and afterload.
The RV has a different response to intermittent positive
Figure 1
Leftward movement of the interventricular septum. (a) Position of the
interventricular septum during systole in normal conditions. 
(b) Dilatation of the right ventricle, which moves the septum over into
the cavity of the left ventricle at the end of prolonged right systole. 
The pericardium surrounds the heart and does not allow excessive
dilatation of the right ventricle without displacement of the interventricular
septum. LV, left ventricle; P, pericardium; RV, right ventricle; S, septum.
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pressure ventilation; the preload decreases but pulmonary
vascular resistance and consequently afterload increase. This
is further accentuated with positive end-expiratory pressure. If
intermittent positive pressure ventilation is necessary in the
setting of RVF, then high levels of plateau pressure and
positive end-expiratory pressure should be avoided to
minimize the right heart–lung interaction. For the same
reason, high respiratory rates, which can lead to air trapping
and intrinsic positive end-expiratory pressure, should be
avoided. The minimal level of plateau pressure, mean airway
pressure and positive end-expiratory pressure necessary for
pulmonary recruitment should be maintained.
Acute respiratory distress syndrome
In ARDS two factors contribute to right heart failure. First,
increased pulmonary vascular resistance occurs as a result of
the distal occlusion of the pulmonary arterial bed. Second,
most patients require mechanical ventilation to maintain
adequate oxygenation and, as described above, intermittent
positive pressure ventilation can worsen RVF. The incidence
of acute cor pulmonale in ARDS is about 25% [8] if a
protective ventilation strategy (low tidal volume/low plateau
pressure) is used. A study conducted in 1985, when high
tidal volume was used (≥13 ml/kg), identified an incidence of
acute cor pulmonale in ARDS of 65% [4,15].
Hypoventilation state
With respiratory failure, as occurs in patients with chronic
obstructive pulmonary disease, some areas of the lungs are
hypoventilated. This stimulates the pulmonary vasoconstrictor
reflex, thereby increasing pulmonary vascular resistance.
Concomitant hypercapnia and acidosis are often present, and
this worsens both vascular resistance and ventricular
contractility. In these situations, acidosis should be corrected
as well as hypercapnia.
Sepsis
Right ventricular dysfunction, as demonstrated with radio-
nuclide angiography and echocardiography, is common in
sepsis (up to 32%) [4,16,17]. RVF should be kept in mind in
all septic patients who do not respond to volume expansion.
Reduced right ventricular contractility
Chronic heart failure
The response to chronic increased afterload of the RV is
characterized by an initial dilatation and then by tricuspid
regurgitation and low cardiac output. In recent years a
number of studies have supported right ventricular perfor-
mance being an important prognostic determinant in chronic
heart failure [2] and, most importantly, right ventricular
ejection fraction (RVEF) and pulmonary arterial pressure are
independent predictors of survival [18].
Right ventricular myocardial infarction
There is a high prevalence of single vessel coronary disease
in myocardial infarction (MI) of the RV compared with MI of
the LV. When shock is present in patients with MI of the RV,
the mortality is high and similar to that in patients with
cardiogenic shock from infarction of the LV [19]. The
aetiology of such MIs can be related back to an occlusion of
the proximal part of the RCA. This leads to depressed right
ventricular function and decreased left ventricular preload.
Cardiac output is low and systemic hypotension appears as a
consequence, even if left ventricular function is normal [20].
Right heart failure can be exacerbated if the posterior
portions of the interventricular septum are also involved,
because the septum plays an important role in right
ventricular contraction [4,21,22].
Pulmonary arterial hypertension is usually absent but MIs
have been reported to occur more frequently when right
ventricular hypertrophy (which can be consequent to
sustained increased afterload) is present. Indeed, many RCA
occlusions do not lead to MI. The simple explanation for this
is that myocardial hypertrophy increases oxygen demand and
thereby leads to more ischaemic damage [10].
Assessment devices
Because the clinical presentation of right heart failure is very
nonspecific, it is difficult to make a diagnosis of RVF by
clinical examination alone. In the ICU scenario there are
essentially two ways to assess right-sided function:
pulmonary artery catheterization and echocardiography. The
latter can be divided into transthoracic and transoesophageal
methods. Magnetic resonance and radionuclide ventriculo-
graphy are two other valid methods of assessment, but
because their use at the bedside is difficult we do not
consider them here. Electrocardiography and troponin
assessment are also useful when MI is suspected.
Pulmonary artery catheter
Pulmonary arterial catheterization is the most invasive and
oldest method of assessing right-sided cardiac function. It is
the only available continuous monitoring device that permits
evaluation of the efficacy of treatment. In fact, it permits
continuous monitoring of right atrial pressure, right ventricular
pressure, pulmonary arterial pressure, pulmonary artery
wedge pressure (PAWP), continuous cardiac output and
mixed venous oxygen saturation. Modern PACs can also be
used to measure RVEF and right ventricular end-diastolic
volume [23-25]. The diagnosis of RVF is made in situations of
systemic hypotension, decreased cardiac output and low
mixed venous saturation, and when there is a high right atrial
pressure that is higher than a usually normal PAWP.
Diagnosis of pulmonary artery hypertension (PAH) is easily
made by assessing pulmonary pressure. Fluid loading in RVF
can be dangerous.
New catheters permit continuous measurement of right
ventricular end-diastolic volume index (RVEDVI) and RVEF.
RVEDVI is a novel preload index. Interestingly, it seems that
better understanding and use of RVEDVI result from its
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consideration together with RVEF, a parameter that can
define the contractility status of the RV. Indeed, as Sarnoff
and Berglund [3] reported, contractility is derived from a
series of ventricular function curves, with each curve having a
particular ejection fraction and optimal preload (end-diastolic
volume). Thus, it appears that correct interpretation of
RVEDVI is strongly dependent on RVEF [26]. Currently, there
is little evidence to support routine use of RVEDVI and RVEF
in RVF.
Table 1 shows how RVEDVI and RVEF can be used to guide
fluid and drug management. In this clinical example, a patient
monitored with a PAC was given fluids and dobutamine. After
the volume challenge the CI did not improve and the RVEDV
increased. The RVEF decreased and the mean pulmonary
artery pressure increased from 18 to 28 mmHg, indicating
that the patient was not responding to volume expansion. The
mixed venous oxygen saturation did not change and lactate
level increased. Consequent administration of dobutamine
without further volume expansion increased RVEF from 25%
to 38%. At the same time, mean pulmonary artery pressure
decreased from 28 to 16 mmHg. Although the CI does not
improve, the improvement in cardiac performance is reflected
by decreases in mean pulmonary artery pressure and lactate
levels, and increases in RVEF and mixed venous oxygen
saturation.
One of the primary aims in the setting of acute RVF is to
achieve a reduction in right ventricular afterload. The best
way to gauge the effectiveness of this treatment strategy is to
monitor the patient continuously. This can only be done using
the PAC.
Echocardiography
The role of echocardiography has expanded in recent years.
The most powerful characteristic of this technique is that it
permits immediate qualitative diagnosis of heart disease,
simultaneously allowing for estimation of flows and pressures.
In order to explore the right side of the heart, transthoracic
echocardiography can be used as long as the patient remains
unventilated. When mechanical ventilation is being used, a
transoesophageal approach should be used, resulting in
better imaging. Diagnosis of RVF is made qualitatively and, as
emphasized by Jardin and Viellard-Baron [4], septal
dyskinesia is the hallmark of RVF. Transoesophageal echo-
cardiography may confirm an initial suspicion of RVF (high
central venous pressure) if absence of the respiratory
variation in vena cava diameter is detected. Both trans-
thoracic and transoesophageal echocardiography can be
used to estimate pulmonary pressures. The qualitative aspect
of echocardiography allows a diagnosis of RVF to be made
along with recognition of its cause. It is possible to recognize
RVF secondary to a PE, ARDS, or coronary obstruction
simply by analyzing the different recorded images [27].
Furthermore, echocardiography can assess both the right
and left sides of the heart, and can allow measurements to be
taken in systolic and diastolic phases that can be repeated,
allowing intermittent monitoring of the efficacy of treatment.
Treatment strategies (with an emphasis on
monitoring techniques)
The aim of treatment for right heart failure is to achieve
optimal ‘contraction status’ by breaking the auto-aggravation
cycle. A decrease in afterload should always be sought and
an adequate preload should be maintained with appropriate
fluid administration. Although overload should be avoided,
hypovolaemia is unacceptable. Inotropes can be used to
optimize ventricular contraction. Afterload can be decreased
with the use of drugs and by minimizing the effects of
ventilation on the heart. While providing these supportive
therapies, definitive therapies such as coronary reperfusion
should be delivered.
Management of myocardial infarction
Reperfusion of the occluded coronary is beneficial and
should be a primary goal in proven right-sided infarction
[28,29]. The goals suggested by Pfisterer [20] for right
ventricular infarction are as follows: early recognition, early
reperfusion, maintenance of adequate preload, reduction in
right ventricular afterload (inotropes, balloon counter-
pulsation), preservation of right ventricular synchrony and
avoidance of vasodilators, nitrates, morphine and β-blockers.
It is very important that the left ventricular pressure be kept as
close to normal as possible; this can help to restore the
normal position of the interventricular septum and thereby
improve contraction of the RV [10].
Critical Care    Vol 10 Suppl 3 Cecconi et al.
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Table 1
Haemodynamic and arterial pressure responses to volume
challenge and dobutamine
Response to 
Response to dobutamine 
Parameter Baseline volume challenge (5 µg/kg per min)
MAP 83 80 74
RAP 12 16 13
MPAP 18 28 16
PAWP 12 12 11
CI 1.8 1.9 1.8
RVEF 33 25 38
RVEDVI 145 190 163
SvO2 54 52 60
Lactate 3.1 3.5 3.2
These measurements are from a 67-year-old critically ill postoperative
patient. See text for further details. CI, cardiac index; MAP, mean
arterial pressure; MPAP, mean pulmonary arterial pressure; PAWP,
pulmonary artery wedge pressure; RAP, right atrial pressure; RVEDVI,
right ventricular end-diastolic volume index; RVEF, right ventricular
ejection fraction; SvO2, mixed venous oxygen saturation.
Fluid therapy
Because of the interventricular dependence phenomenon,
volume overload can dilate the RV so much that it may impair
left ventricular function and the entire circulation. Conversely,
adequate fluid loading is necessary to achieve optimal
contraction. So what should happen at the bedside in a
patient with RVF? In the ICU fluid therapy is often guided by
fluid challenges. Mercat and coworkers [14] discovered that,
in acute PE, fluid challenges improve cardiac output,
especially in patients with low baseline atrial pressure, who
probably represent those in whom interventricular
dependence is not yet playing a substantial role. Using mean
pulmonary arterial pressure as a guide to fluid challenge, it
seemed reasonable to stop filling beyond a mean pulmonary
artery pressure of 30 mmHg [5,30]. This is supported by
findings reported by Atherton and coworkers [31], even
though their population included patients with chronic heart
failure. In that study the investigators used a device that
results in acute volume unloading by generating lower body
suction of 30 mmHg, and they measured how right and left
volumes changed. Interestingly, among the patients with
heart failure, those with an increased left ventricular end-
diastolic volume after the volume unloading were also those
with higher right resting atrial pressures, mean pulmonary
arterial pressure, and PAWP.
During the past few years a new way to assess fluid
responsiveness in ventilated patients has become popular.
Pulse pressure variation, evaluated by a simple analysis of the
arterial pressure wave, has been proven to identify patients
who may benefit from fluid challenge. In the setting of the
patient with RVF undergoing mechanical ventilation, pulse
pressure variation can be high not because of hypovolaemia
alone but also because of ventricular impairment exacerbated
by the mechanical ventilation [27,32].
Therefore, if a fluid challenge is followed by an increase in
filling pressure without change in cardiac output, then fluid
loading should be stopped. PAC is a valuable tool in this
context because it allows the clinician to assess pulmonary
pressure and CI on a continuous basis. The efficacy of fluid
challenge can be monitored by watching changes in CI, SVI,
RVEDVI and RVEF. Fluid removal with diuretics or haemo-
filtration may then be beneficial [5]. However, fluid withdrawal
is effected, it is important that cardiac output monitoring be
used to assess the efficacy and safety of treatment.
Drugs
Drugs are employed either to decrease pulmonary vascular
resistance or to increase cardiac contractility.
Vasodilators
Inhaled nitric oxide (iNO) is a vasodilator that can be given to
ventilated patients. It causes vasodilatation by increasing
levels of cGMP in vascular smooth muscle cells. cGMP has a
short half-life because it is degraded by endogenous
phosphodiesterases. On entering the pulmonary circulation,
iNO binds with plasma proteins and is immediately
inactivated by haemoglobin. In this way its effects are
localized solely to the pulmonary vasculature [33]. Moreover,
its effect is to vasodilate only ventilated areas of the lungs,
maintaining an efficient ventilation/perfusion ratio. Indeed,
systemic administration of vasodilators such as nitroglycerine
or prostaglandin E1 can improve RVF, but by being
unselective for ventilated areas these agents can worsen the
ventilation/perfusion ratio [34,35]. iNO is considered the
‘gold standard’ in the management of PAH. Its role has been
studied in primary PAH, and in this way it has been used to
identify patients who would benefit from long-term treatment
with nifedipine [36]. In acute RVF its ability to lower
pulmonary artery resistance and pressure has been proved,
even though it has not been demonstrated to decrease
mortality in those patients who respond to the therapy [37].
iNO can be associated with a rebound increase in pulmonary
arterial pressure, especially when its use is prolonged and its
withdrawal sudden [38]. Its role is more controversial when we
consider its effect on the LV. Indeed, some reports indicate that
a decrease in cardiac output and an increase in PAWP may
occur during iNO therapy for left ventricular impairment
[39,40]. On the other hand, in a small study in patients with
severe isolated right ventricular dysfunction [37] it was found
that high concentrations of iNO (35-40 parts/million) not only
decrease afterload but also increase cardiac output.
Considering all the published studies, iNO appears to be a
rapid acting and effective treatment in acute RVF.
Prostacyclin (prostaglandin I2) is both a vasodilator and a
potent inhibitor of platelet aggregation. It can be administered
systemically or locally as inhaled prostacyclin as an alternative
to iNO [5]. The preferred method of administration is
inhalation for two reasons: first, it vasodilates ventilated areas
of lung; and second, no PAH rebound on finishing treatment
has been described. Systemic prostacyclin is available for
administration by intravenous [41], subcutaneous [42], and
oral [43] routes. Iloprost is a prostacyclin derivate molecule
(carbacyclin). In comparison with prostacyclin and iNO, it has
a longer half-life and its effects persist for 1 hour after
administration [5].
Sildenafil is an inhibitor of phosphodiesterases that was
initially used in the management of erectile dysfunction. Its
effect is greater on pulmonary than on the systemic
circulation because it inhibits phosphodiesterase-5 more than
its analogous isoforms. This particular enzyme is expressed
mainly in pulmonary vessels and in the corpora cavernosa.
Oral administration has proven to reduce hypoxia-induced
PAH. In cardiac surgery sildenafil has been used to wean
patients from inhaled iNO [44]. Its synergistic effects both
with iNO and iloprost have been demonstrated.
Interestingly, Ghofrani and coworkers [45] found that oral
sildenafil but not intravenous prostacyclin induced pulmonary
Available online http://ccforum.com/content/10/S3/S5
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vasodilatation in patients with pulmonary fibrosis, thereby
maintaining an optimal ventilation/perfusion ratio.
Combinations of sildenafil and iNO can be used to achieve
effects on PAH better than those with administration of a
single drug [46].
Inotropes
Selective right heart inotropes do not exist. Contractility can
be manipulated with the use of inotropes that are usually
used in the management of left ventricular failure. These
drugs act on the entire myocardium, improving both right and
left ventricular contractility. In fact, increased left ventricular
contraction can, in turn, facilitate right ventricular contraction.
In the ICU β-mimetics such as dobutamine can be used to
promote myocardial contraction and to improve cardiac
output. Indeed, phosphodiesterase inhibitors and a new class
of drugs, namely the calcium sensitizers, can also be used.
Levosimendan is the first calcium sensitizer to be employed in
clinical practice. In animal models, in comparison with
milrinone, levosimendan was reported to increase cardiac
output without increasing intracellular calcium levels, and so
without increasing oxygen demand [47]. Moreover, the LIDO
trial reported lower mortality at 6 months for levosimendan in
comparison with dobutamine in low output cardiac failure
[48]. More important in the context of right heart failure is that
it acts as a vasodilator by opening ATP-sensitive potassium
channels. It decreases pulmonary capillary wedge pressure,
pulmonary artery pressure and mean right atrial pressure.
Compared with dobutamine, levosimendan produces a similar
increase in cardiac output but profoundly greater decreases
in PAWP [49]. However, it is not a selective pulmonary
vasodilator, and can lead to systemic hypotension. Whatever
inotrope is used, cardiac output monitoring is essential for
guiding therapy. The PAC can provide the clinician with
information on both cardiac output and pulmonary pressure
changes during inotrope use.
Systemic vasoconstrictors
It is not easy to arrive at a clinical diagnosis of RVF. The first
clinical sign is commonly systemic hypotension. In the ICU
this is usually treated with fluid administration and infusion of
a vasoconstrictor. However, caution is needed because
vasoconstrictors can also have a detrimental effect on the
pulmonary vasculature by increasing pulmonary vascular
resistance. In clinical practice, norepinephrine (noradrenaline)
increases mean arterial pressure and this in turn improves
coronary perfusion, as well as left and right ventricular
contraction. Animal studies demonstrated the effect of
norepinephrine on pulmonary resistance during heart failure
[50,51] and revealed that norepinephrine restores mean
arterial pressure and improves cardiac output. Right
ventricular impairment can persist for some time after
resolution of PAH [52]. In one model of RVF, after elimination
of PAH, dobutamine was shown to be better than
noradrenaline in restoring both cardiac output and mean
arterial pressure [51].
Conclusion
RVF is a commonly under-diagnosed condition in the ICU.
The diagnosis can be made using either pulmonary arterial
catheterization or echocardiography. Treating the cause,
decreasing afterload and restoring good contractility are
paramount; the aims of therapy should be to reduce
excessive pulmonary artery pressures and to improve cardiac
output and systemic arterial pressure. Fluids should be given
only to counteract hypovolaemia (because the risk for
worsening both right and left contraction is high), with fluid
loading guided by cardiac output monitoring. Pulmonary
vasodilators and inotropes may be indicated. Monitoring the
results of treatment can be achieved continuously with an in
situ PAC and repeated echocardiographic measurements.
RVEF and RVEDVI are two new variables that may be useful
in monitoring right heart performance in the setting of RVF.
Studies evaluating the efficacy of therapy guided by such
variables are awaited.
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